1:30 am The Value Proposition of Early Identification & Intervention of Kidney Disease
8:20 am Chair’s Opening Remarks
Endpoints: How Do We Get a Drug to Market? Navigating Trial Endpoints in a Therapeutic Area without Regulatory Precedent
8:30 am Renal Function Surrogates for Trial Endpoints & Clinical Decision Support: Are We Reshuffling an Old Deck or Adding New Cards to the Table?
9:00 am Phase 2a Results, Phase 2b Study Design, & Investigations into the Mechanism of Action of Verinurad, a URAT1 Inhibitor, in Development for CKD & Heart Failure
9:30 am Selective ETA receptor antagonist ATRASENTAN for the Treatment of Primary Glomerular Diseases
10:30 am Morning Break & Networking
Forward Thinking Questions to Shape the Next Generation of Drug Development Decisions
Translational Drug Development Track
Chaired By: Jeremy Duffield, Global Head of Human Biology, Vertex Pharmaceuticals
Later Stage Clinical& Commercial Drug Development Track
Chaired By: Annadoir Staveley, Associate Director of Clinical Disclosure& Data Sharing, Ethics& Compliance, Otsuka Pharmaceuticals
Harnessing the AI to Maximize Data Interrogation & Debating the Importance of Renal Fibrosis
11.00 Use of Artificial Intelligence in CKD Drug Discovery & Disease Understanding
Pernille Hansen, Senior Director & Head of Bioscience, AstraZeneca
11.30 Panel Discussion: Understanding Renal Fibrosis as a Hallmark of CKD & Debating if Targeting TGF is Best to Reverse it
Matt Breyer, Distinguished Scientist, Janssen
Ravi Kumar, Senior Vice President & Chief Scientific Officer, Acceleron Pharma
Hitesh Soni, Renal Fibrosis Gene Therapy Lead, Renascent Biosciences
Scott MacDonnell, Associate Director, Cardiovascular & Fibrosis Research, Regeneron Pharmaceuticals
Considering Costs of CKD as a Significant Public Health & Orphan Indications
11.00 The 3 “R”s of Orphan Kidney Disease Research: Risk, Resources & Reimbursement
Frank Czerwiec, Chief Medical Officer, Goldfinch Bio
11.30 Implementing Evidence for CKD Care : Program Development & Early findings at CVS Kidney Care
Bruce Culleton, Vice President & Chief Medical Officer, Kidney Care, CVS Health